Prognostic importance of the soluble plasminogen activator receptor; suPAR, in plasma from rectal cancer patients

被引:38
作者
Fernebro, E [1 ]
Madsen, RR
Fernö, M
Brünner, N
Bendahl, PO
Christensen, IJ
Johnson, A
Nilbert, M
机构
[1] Univ Lund Hosp, Jubileum Inst, Dept Oncol, S-22185 Lund, Sweden
[2] Copenhagen Univ Hosp, Finsen Lab, Copenhagen, Denmark
[3] Akad Hosp, Dept Oncol, Uppsala, Sweden
关键词
soluble plasminogen activator receptor (suPAR); rectal cancer; prognostic marker;
D O I
10.1016/S0959-8049(00)00422-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer is one of the most common tumour types with approximately one third of the tumours located within the rectum. Rectal cancer differs somewhat from colon cancer, e.g. regarding the method of operation and the use of preoperative radiotherapy due to a tendency for local tumour recurrence. Proteolytic enzymes have been identified as key molecules in tumour invasion and metastasis, and factors within the urokinase-plasminogen activation (uPA) system have been associated with prognosis in several tumour types, including colorectal cancer. Recently, methods have been developed to analyse the soluble fraction of the plasminogen activator receptor (suPAR) in blood samples. An association between elevated suPAR levels and poor prognosis has recently been demonstrated in colorectal cancer. We have measured suPAR levels in pretreatment plasma samples from 173 rectal cancer patients in order to confirm its prognostic strength in this clinical entity. suPAR levels were determined in ethylenediamine tetraacetic acid (EDTA) plasma by a kinetic enzyme-linked immunosorbent assay (ELISA) and analysed with respect to sex, age, Dukes' stage, tumour differentiation grade and survival. In a univariate analysis, continuous suPAR plasma levels were associated with survival (P<0.001) with shorter survival among patients with high suPAR values. Patients with suPAR values within the upper quartile had significantly shorter survival (hazard ratio (HR) 2.2, 95% confidence interval (CI) 1.3-43.7, P=0.002). In a multivariate Cox analysis, increasing suPAR values predicted shorter survival independent from Dukes' stage and tumour differentiation grade with an adjusted HR of 2.2 per ng/ml suPAR (95% CI 1.2-4.0, P=0.01). This study thus confirms that measurement of suPAR in preoperative plasma samples gives independent prognostic information in rectal cancer patients, higher values being associated with shorter survival. <(c)> 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:486 / 491
页数:6
相关论文
共 21 条
[1]  
*AM JOINT COMM CAN, 1998, CANC STAG MAN
[2]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[3]  
2-Z
[4]  
Brünner N, 1999, APMIS, V107, P160
[5]  
Duffy MJ, 1996, CLIN CANCER RES, V2, P613
[6]   UROKINASE PLASMINOGEN-ACTIVATOR AND UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR IN BREAST-CANCER [J].
DUGGAN, C ;
MAGUIRE, T ;
MCDERMOTT, E ;
OHIGGINS, N ;
FENNELLY, JJ ;
DUFFY, MJ .
INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (05) :597-600
[7]   UROKINASE RECEPTOR AND COLORECTAL-CANCER SURVIVAL [J].
GANESH, S ;
SIER, CFM ;
HEERDING, MM ;
GRIFFIOEN, G ;
LAMERS, CBHW ;
VERSPAGET, HW .
LANCET, 1994, 344 (8919) :401-402
[8]  
GrondahlHansen J, 1995, CLIN CANCER RES, V1, P1079
[9]   Soluble urokinase receptor released from human carcinoma cells:: a plasma parameter for xenograft tumour studies [J].
Holst-Hansen, C ;
Hamers, MJAG ;
Johannessen, BE ;
Brünner, N ;
Stephens, RW .
BRITISH JOURNAL OF CANCER, 1999, 81 (02) :203-211
[10]   The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction [J].
Hoyer-Hansen, G ;
Behrendt, N ;
Ploug, M ;
Dano, K ;
Preissner, KT .
FEBS LETTERS, 1997, 420 (01) :79-85